Figure 4.

Histidine–alanine–valine peptide inhibited pressure-induced myogenic vasoconstriction. The reduced slope of myogenic pressure–diameter relationship (i.e., index of myogenic gain) as determined by regression analyses demonstrates the ability of HAV peptide to inhibit the myogenic response. (A) Percentage control diameter of isolated arterioles exposed to increments in intraluminal pressure before and after addition of the HAV peptide treatment. (B) Slope of the pressure–diameter regression line before the addition of the antibody and while in the presence of the abluminal inhibitory peptide (n = 6). (C) Percentage control diameter of isolated arterioles exposed to increments in intraluminal pressure before and after the control anti-VE-Cadherin antibody treatment. (D) Slope of the pressure–diameter regression line before the addition of the peptide and while in the presence of the abluminal control peptide (n = 6). Data are presented as mean ± SEM. *Significantly different from the first series of step increments in pressure in the same vessel.